MEDA Pharma GmbH & Co. KG

Quick facts

Marketed products

• Flecainide controlled release · Cardiovascular
  Flecainide is a Class IC antiarrhythmic that blocks cardiac sodium channels to slow conduction velocity and suppress abnormal electrical activity in the heart.
• fluticasone propionate nasal spray + loratadine · Allergy/Immunology
  This combination reduces allergic rhinitis symptoms by suppressing nasal inflammation via corticosteroid action and blocking histamine-mediated allergic responses via H1-receptor antagonism.

Phase 3 pipeline

• Aldara (Imiquimod) · Dermatology, Oncology, Immunology
  Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat viral infections and skin cancers.

Phase 2 pipeline

• Combination DSCG and Reproterol · Respiratory
  DSCG inhibits mast cell degranulation and reduces inflammation, while Reproterol is a beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle.
• Foradil P 12µg
• Foradil P 24µg · Respiratory
  Foradil P 24µg is a long-acting beta2-adrenergic receptor agonist (LABA) used to control and prevent bronchospasm in patients with asthma and COPD.
• Formatris 12µg
• Formatris 24µg

Phase 1 pipeline

• Azelastine mono
• Fluticasone mono

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• MEDA Pharma GmbH & Co. KG portfolio CI brief
• MEDA Pharma GmbH & Co. KG pipeline updates RSS